| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.1 | 0.1 | 0.0 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 0.1 | 0.2 | 0.0 |
| Profit before exceptional items & tax | -0.4 | -0.5 | -0.4 |
| Profit before tax | -0.4 | -0.5 | -0.4 |
| Net profit | -0.4 | -0.5 | -0.4 |
| Operating margin | -400.0% | -250.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Operating profit, quarter on quarter | +33.30% |
|---|
BSE results filing, NSE: TRABI. Figures extracted from the filing.
Transgene Biotek Ltd: key numbers
- Share price
- ₹2.37
- Market cap
- ₹17.96 Cr
- Revenue (annual)
- ₹0.21 Cr
- Net profit (annual)
- ₹-1.65 Cr
- P/E (TTM)
- -11.2×Sector 53.1×
- Promoter holding
- 23.64%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Transgene Biotek Ltd
All →Transgene Biotek Annual General Meeting
Transgene Biotek has received ROC approval to extend its 36th AGM deadline by three months. The meeting for FY2025-26 will now be held by December 31, 2026.
Transgene Biotek Management Change
Transgene Biotek Ltd announced the resignation of M/s Vasavi & Co. as Statutory Auditors, effective immediately. The auditors cited pre-occupation with other assignments as the reason.
Transgene Biotek Other Announcement
Transgene Biotek submitted its quarterly shareholding pattern for the period ending December 2016. The company noted that certain promoter shares remain in physical form pending listing approval.
Transgene Biotek Management Change
Transgene Biotek Limited has appointed M/s Manisha Dubey & Associates as Internal Auditors for a 12-month term. The board approved the appointment during its August 7, 2026 meeting.
- Execution
- 12 months
Transgene Biotek Board Meeting Date
Transgene Biotek Limited scheduled a board meeting for August 07, 2026, to consider quarterly financial results and AGM extension.
Transgene Biotek Capital Structure Change
Transgene Biotek allotted 1,00,00,000 equity shares worth Rs.10 Crore to its promoter on a preferential basis. The allotment converts existing unsecured promoter loans into equity.
- Value
- ₹10.00 Cr